Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NBP1-78295 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NBP1-78295, RRID:AB_11032627
- Product name
- Rabbit Polyclonal BTK Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 0.1 ml
- Concentration
- 1.09 mg/ml
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation.
A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
Wang SP, Iwata S, Nakayamada S, Niiro H, Jabbarzadeh-Tabrizi S, Kondo M, Kubo S, Yoshikawa M, Tanaka Y
Rheumatology (Oxford, England) 2015 Aug;54(8):1488-97
Rheumatology (Oxford, England) 2015 Aug;54(8):1488-97
A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
Eda H, Santo L, Cirstea DD, Yee AJ, Scullen TA, Nemani N, Mishima Y, Waterman PR, Arastu-Kapur S, Evans E, Singh J, Kirk CJ, Westlin WF, Raje NS
Leukemia 2014 Sep;28(9):1892-901
Leukemia 2014 Sep;28(9):1892-901
Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
Gleixner KV, Peter B, Blatt K, Suppan V, Reiter A, Radia D, Hadzijusufovic E, Valent P
Haematologica 2013 Sep;98(9):1450-7
Haematologica 2013 Sep;98(9):1450-7
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: BTK [p Tyr223] Antibody [NBP1-78295] - WB analysis of BTKpY223 on Ramos whole cell lysate with peptide competition: 1. ab only, 2. 200 molar excess unmodified immunizing peptide and 3. 200 molar excess modified immunizing peptide.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry: BTK [p Tyr223] Antibody [NBP1-78295] - IHC analysis of BTK in kidney cancer xenograft using DAB with hematoxylin counterstain.
